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Abstract
In this study, we developed a methodology to improve the survival, vascular differentiation and regenerative potential of
umbilical cord blood (UCB)-derived hematopoietic stem cells (CD34+ cells), by co-culturing the stem cells in a 3D fibrin gel
with CD34+-derived endothelial cells (ECs). ECs differentiated from CD34+ cells appear to have superior angiogenic
properties to fully differentiated ECs, such as human umbilical vein endothelial cells (HUVECs). Our results indicate that the
pro-survival effect of CD34+-derived ECs on CD34+ cells is mediated, at least in part, by bioactive factors released from ECs.
This effect likely involves the secretion of novel cytokines, including interleukin-17 (IL-17) and interleukin-10 (IL-10), and the
activation of the ERK 1/2 pathway in CD34+ cells. We also show that the endothelial differentiation of CD34+ cells in co-
culture with CD34+-derived ECs is mediated by a combination of soluble and insoluble factors. The regenerative potential of
this co-culture system was demonstrated in a chronic wound diabetic animal model. The co-transplantation of CD34+ cells
with CD34+-derived ECs improved the wound healing relatively to controls, by decreasing the inflammatory reaction and
increasing the neovascularization of the wound.
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Introduction
It is estimated that 15% of the diabetic patients have non-
healing foot ulcerations [1,2]. In recent years, there have been
efforts to develop new advanced methodologies to heal chronic
wounds, including the use of topic growth factors or cell-based
therapies [3]. Some of these therapies have been approved by the
Food and Drug Administration (FDA); however, more effective
ways for the treatment of chronic wounds are needed, especially in
diabetic patients [1,4].
Recent data show that healthy adult stem/progenitor cells
improve the healing of diabetic chronic wounds [5]. It has been
shown that peripheral blood-derived CD34+ cells, but not CD34-
cells, can accelerate the vascularization and healing of diabetic
wounds [5]. However, the vasculogenic potential of adult blood-
derived cells appears to be reduced by diabetes [5,6]. Recent
studies tried to overcome this issue by using fetal [7] or adult
mesenchymal stem cells [8], yet, the isolation of stem cells from
fetal aorta poses several problems for future clinical application,
while mesenchymal stem cells isolated from diabetic patients might
have impaired properties due to ageing and disease.
Human umbilical cord blood (UCB) can be a potential source of
healthy endothelial progenitor cells for the healing of chronic
wounds in diabetic patients. These cells are obtained non-
invasively, can be stored for more than 15 years without loosing
biological properties, and they have low immunogenicity, which
makes them an interesting candidate for allogeneic transplantation
[9,10]. Improvement in wound healing has been reported recently
in two human non-diabetic patients who received topically UCB-
derived CD34+ cells in a fibrin gel [11], although the underlying
regenerative mechanism has not be determined. Despite this
potential, human umbilical cord blood stem cells have not been
used for wound healing in diabetic patients, whose healing process
is impaired or even inexistent.
In the present study, we investigated the use of UCB-derived
CD34+ cells to promote the healing of diabetic wounds when
administered topically in a fibrin gel. To enhance the therapeutic
effect of CD34+ cells, they were co-cultured with endothelial cells
(ECs) derived from CD34+ cells. In vitro data show that CD34+
-derived ECs co-cultured with CD34+ cells improve cell survival
and contribute to the differentiation of CD34+ cells into ECs. We
further show that the co-culture system, but not CD34+ cells or
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CD34+-derived ECs alone, can improve the healing kinetics in a
diabetic animal model. The regenerative effect is mediated by both
anti-inflammatory and pro-angiogenic processes. We anticipate
that this co-culture approach might be used in other contexts to
enhance the efficacy of stem cells.
Materials and Methods
An expanded Materials and Methods section is provided in the
online data supplement (Material and Methods S1).
Isolation of CD34+ cells from UCB
All human umbilical cord blood samples were collected from
donors, who signed an informed consent form, in compliance with
Portuguese legislation. The collection was approved by the ethical
committee of Hospital Infante D. Pedro. The samples were stored
in sterile bags containing 35 mL of citrate-phosphate-dextrose
anticoagulant solution. CD34+ cells were isolated from mononu-
clear cells, obtained from UCB samples after Ficoll (Histopaque-
1077 Hybri Max; Sigma-Aldrich, St. Louis, USA) density gradient
separation. CD34+ cells were positively selected (2 times) using the
mini-MACS immunomagnetic separation system (Miltenyi Biotec,
Bergisch Gladbach, Germany, http://www.miltenyibiotec.com),
according to the manufacturer’s recommendations. CD34+ cells
were immediately used for cell encapsulation studies or in vivo
experiments without further treatment.
Differentiation of CD34+ cells into ECs
Isolated CD34+ cells were transferred onto 1% (w/v) gelatin-
coated 24-well plates (26105 cells/well) and incubated in
endothelial growth medium (EGM-2; Lonza, Gaithersburg, MD,
USA) with 20% (v/v) fetal bovine serum (FBS; Invitrogen,
Carlsbad, USA) and 50 ng/mL vascular endothelial growth factor
(VEGF165; PrepoTech Inc., Rocky Hill, USA), at 5% CO2, 37uC.
After 5 days and then every other day, half of the volume of the
medium was replaced with fresh one. At the end of the
differentiation assay, expression of EC markers was evaluated by
fluorescence-activated cell sorting (FACS) and immunofluores-
cence staining. The functionality of the cells was evaluated by
incubating the cells with acetylated low-density lipoprotein (DiI-
Ac-LDL; Biomedical Technologies, Stroughton, USA).
Cell encapsulation in fibrin gels
The fibrin gel preparation procedure can be found in the online
data supplement (Material and Methods S1). CD34+ cells
(between 0.56105 and 36105), CD34+ cells (16105) in co-culture
with CD34+-derived ECs (0.356105), CD34+-derived ECs
(0.356105) or human umbilical vein endothelial cells (HUVECs)
(Lonza) (0.356105) were encapsulated in fibrin gels (50 mL). Cells
were centrifuged and ressuspended in the fibrin gel precursor
solution, in 1 mL sterile syringes with cut tips. Polymerization was
initiated at 37uC and allowed to proceed over 30 min. After
polymerization, the cell constructs were removed from the syringe
and placed in 24-well plates containing specific medium (see below
for details), for up to 10 days. Viability and metabolic activity of
encapsulated cells were evaluated according to methodologies
described in the online data supplement (Material and
Methods S1).
Cell characterization
Detailed protocols for FACS, immunostaining and quantitative
reverse transcription-polymerase chain reaction (qRT-PCR)
analysis are presented in the online supplement Material and
Methods S1 and primer sequences on Table S1.
Cytokine secretion analyses
Cell culture supernatants and protein lysates were evaluated for
the presence of cytokines using a Bio-Plex Pro Human Cytokine
17-Plex Panel Assay or a Bio-Plex Pro Mouse Cytokine 8-Plex
Assay, respectively (both from Bio-Rad, Hercules, CA, USA),
according to manufacturer’s instructions, and further described in
the online supplement.
Analysis of total and phosphorylated Akt and ERK protein
levels
Activation of Akt and extracellular signal-regulated kinase
(ERK) in CD34+ cells and CD34+-derived ECs was promoted by
starving the cells for 19 h in serum-free M199 medium (with
Earle’s Salts and L-glutamine; Sigma-Aldrich) and then treating
them for 10 min, by replacing the medium by fresh M199 or cell-
conditioned M199. Following treatment, proteins were isolated
from the cells, and the levels of Akt and ERK phosphorylation
determined using Bio-Plex kits from Bio-Rad, according to
manufacturer’s instructions.
CD34+ cell adhesion to different substrates
A 24-well plate was coated with several substrates, including
fibrin gel (500 mL per well), collagen type I gel (500 mL per well,
from a solution of 2.5 mg/mL rat tail collagen I; BD Biosciences
Pharmingen, San Jose, CA, USA), or fibronectin (Roche Applied
Science, Mannheim, Germany) [50 mg/mL, in Phosphate Buffer
Saline (PBS; Sigma-Aldrich)]. CD34+ cells labeled with 5(6)-
carboxyfluorescein diacetate N-succinimidyl ester (CFSE) (Sigma-
Aldrich) and suspended in EGM-2 medium (16105/mL) were
seeded on the coated or uncoated (polystyrene) wells and
incubated for 3 h at 37uC. After this time, the culture medium
was removed and the cells attached to the wells washed twice with
PBS. Attached cells were then counted after photographing six
random microscope fields (6200 magnification) for each replicate.
CD34+ cell adhesion and differentiation on top of fibrin
gels
Fibrin gel precursor solution (500 mL per well) was added to a 24-
well plate and allowed to polymerize. For the adhesion assay, CFSE-
labeled CD34+ cells (16105, unless otherwise stated) were seeded on
top of a fibrin gel and cultured in EGM-2 medium, either alone or
in co-culture with CD34+-derived ECs (0.356105), or in CD34+-
derived EC conditioned medium. The conditioned medium was
obtained by culturing CD34+-derived ECs in EGM-2 medium for
48 h, at a density of 0.756105 cells per mL (24-well plate), removing
the medium and sterilizing it by filtration. The number of adherent
CD34+ cells was determined in a phase-contrast microscope or in a
fluorescence microscope after 7 days of culture, following the
removal of the non-adherent cells, by washing with PBS. The
differentiation potential of CD34+ cells (16105) on top of fibrin gels
was assessed in similar conditions. After 7 days, the ability of the
CD34+ cells to uptake DiI-Ac-LDL was determined by fluorescence
microscopy and compared to the initial level of uptake of DiI-Ac-
LDL by CD34+ cells immediately following their isolation.
In vivo experiments
Animal protocols (see online data for further details) were
approved by the Ethics Committee of the Faculty of Medicine of
the University of Coimbra (ID 2008/001). Diabetes mellitus was
induced by intraperitoneal injection of streptozotocin (Sigma-
Aldrich) in male C57BL/6 mice (10-12 week-old), purchased from
Charles River (Wilmington, MA, USA). Only animals with glucose
levels greater than 300 mg/dL were used in this study.
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Six to eight weeks following diabetes induction, the animals
were anesthetized, the dorsolumbar skin shaved and disinfected
and two 6 mm-diameter dorsal full-thickness excisional wounds
were created with a sterile biopsy punch in each animal. The
wounds were then covered with 25 mL PBS, 25 mL fibrin gel
alone, or 25 mL fibrin gel precursor solution containing 16105
human umbilical cord blood CD34+ cells (unless otherwise stated),
either alone or in combination with 0.356105 CD34+-derived
ECs. All cells had been previously labeled with CFSE. After
surgery, the animals were maintained in individual cages with food
and water ad libitum and in a temperature and humidity-controlled
environment. The rate of wound closure was determined over ten
days. At the end of the study, animals were sacrificed by cervical
dislocation and 10 mm-diameter skin biopsies analyzed by RT-
PCR, immunofluorescence or Bio-Plex Pro Mouse Cytokine 8-
Plex Assay.
Statistical analysis
For analysis involving three or more groups, ANOVA was used,
followed by a Student-Newman-Keuls post hoc test. For analysis of
two groups, a paired t-test was used. Statistical analysis was
performed using GraphPad Prism software (San Diego, CA, USA,
http://www.graphpad.com/). Results were considered significant
when P#0.05.
Results
Differentiation of UCB-derived CD34+ cells into ECs
Results obtained by immunocytochemistry show that undiffer-
entiated CD34+ cells express high levels of CD34 (100%) and
CD31 markers (85.4617.0%, n=8), incorporate moderate levels
of Ac-LDL (12.8610.4%, n=13) and show no expression of the
definitive endothelial marker vWF (Fig. 1A). FACS analyses
confirm their high expression of CD34 and CD31 markers, high
expression of CD45, a typical marker of hematopoietic cells, and
no expression of Flk-1/KDR and CD14 (a marker mainly
expressed by macrophages) (Fig. 1B). Similarly, no vWF
expression and high CD34 expression were observed at gene level
(Fig. 2B). Therefore, the UCB-derived CD34+ population used in
this work is CD34+CD45+CD31+KDR2vWF2CD142.
To differentiate CD34+ cells into ECs, we cultured CD34+ cells
(100,000 cells per cm2) in gelatin-coated dishes in EGM-2 medium
with 20% (v/v) of FBS and 50 ng/mL of VEGF165. Typically after
15–20 days of culture, CD34+ cells attached to the culture dish with a
Figure 1. Protein expression in undifferentiated CD34+ cells and their endothelial progenies. A) Immunofluorescence results for
undifferentiated CD34+ cells. Bar corresponds to 20 mm. B, C) FACS analysis of (B) undifferentiated CD34+ cells and (C) CD34+-derived ECs at passage 1
(1st P) and 3 (3rd P). Percentages of positive cells were calculated based on the isotype controls (grey plot) and are shown in the histogram plots.
doi:10.1371/journal.pone.0016114.g001
Interplay of Stem Cells with Endothelial Cells
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16114
cobblestone-like morphology and expressed high levels of EC
markers, including CD31, CD34 and Flk-1/KDR over time
(Fig. 1C). In addition, differentiated CD34+ cells stained positively
for CD31 and VE-cadherin at cell-cell adherent junctions, produced
vWF and were able to incorporate Ac-LDL (Fig. 2A), typical markers
found in ECs (Fig. S1). In line with the EC phenotype, these cells do
not express a-SMA, a smooth muscle cell marker (Fig. 2A).
Quantitative RT-PCR (qRT-PCR) analyses showed that
CD34+-derived ECs express the EC markers CD34 and vWF
and produce angiogenic growth factors including VEGF, PlGF
and bFGF (Fig. 2B). The expression of PlGF growth factor is
higher on CD34+-derived ECs than on CD34+ cells, while the
opposite was observed for bFGF. In addition, qRT-PCR results
show that the expression of angiogenic growth factors is higher on
CD34+-derived ECs than on HUVECs.
The ability of CD34+-derived ECs to form cord-like structures
was also assessed by culturing these cells in the basement
membrane Matrigel. Similarly to HUVECs, CD34+-derived ECs
were able to spontaneously reorganize into cord-like structures
when maintained in culture for 15 h (Fig. S2). Yet, the
angiogenesis potential of CD34+-derived ECs is higher than that
of HUVECs, as confirmed by the higher number of sprouts and
network length (Fig. 2C).
Fibrin gels as three-dimensional scaffolds for CD34+ and
CD34+-derived ECs
Fibrin has been shown to provide a permissive environment for
endothelial cell adhesion, migration and three-dimensional
organization [12,13]. However, it is unclear whether fibrin gels
might be an effective substrate for CD34+ cell adhesion. For this
Figure 2. Characterization of CD34+-derived ECs. A) Immunofluorescence analysis. Bar corresponds to 40 mm. B) Quantitative RT-PCR analysis.
Results are average 6 SD, n=4. C) Quantification of cord length and number of sprouts at 15 h and 48 h. Counts were performed using a
magnification of6100. Results are average 6 SD, n=3. *, **, *** denote statistical significance (P,0.05, P,0.01, P,0.001, respectively).
doi:10.1371/journal.pone.0016114.g002
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purpose, CD34+ cells were plated on 24-well plates coated with
fibrin gels or different substrates and cell adhesion evaluated by
microscopy, by counting the cells attached after 3 h. CD34+ cells
demonstrated greater initial adhesion to fibrin gels than to
polystyrene dishes, collagen and fibronectin (Fig. 3). The number
of CD34+ cells adherent to fibrin was 2.0- (P,0.05), 4.0- (P,0.01)
and 3.0-fold (P,0.01) greater than to collagen, polystyrene and
fibronectin, respectively.
Next, we used fibrin gels to encapsulate CD34+ cells. Initially,
we studied the effect of cell number to gel volume for optimal cell
survival. Cell viability did not change significantly after 10 days for
the different cell densities tested (Fig. S3). Therefore, 100,000
CD34+ cells per 50 mL of fibrin gel were used in subsequent tests.
Fibrin gels resist the degradation initiated by the metalloprotease
enzymes released by CD34+ cells, or CD34+-derived ECs (35,000
cells), or the co-culture of CD34+ cells with CD34+-derived ECs
(100,000: 35,000 cells, respectively) for 10 days (Fig. S4).
Furthermore, cell traction does not reduce significantly the gel
diameter over time in all the experimental groups (Fig. S4).
Cell survival is improved by co-culturing CD34+ cells with
CD34+-derived ECs
CD34+ cells encapsulated in fibrin gels have a viability of 60-70%
at day 2 and day 10, statistically lower (n=6, P,0.001) than the one
observed for CD34+-derived ECs (Fig. 4A). An MTT assay was
used to determine the metabolic activity of cells encapsulated in the
gels (Fig. 4B). The metabolic activity of CD34+ cells at day 10 was
approximately 90% of the initial activity (day 2), suggesting that cells
were in a non-proliferative state.
Quantitative LIVE/DEAD and MTT analyses indicate a
significant increase in cell viability and proliferation for CD34+
cells co-cultured with CD34+-derived ECs (n=6, P,0.01 or
P,0.001) (Figs. 4A and 4B). This effect was observed for days 6
and 10, although more pronounced at day 10, in terms of
metabolic activity. In contrast, HUVECs did not affect the
viability of CD34+ cells (n=6, P.0.05) (Fig. 4C), indicating that
the pro-survival effect is specifically mediated by CD34+-derived
ECs. Importantly, addition of CD34+-derived EC-conditioned
medium to cell constructs formed by CD34+ cells resulted in a
significant increase in cell viability (n=6, P,0.001) (Fig. 4C).
These results suggest that the pro-survival effect of CD34+-derived
ECs on CD34+ cells is mediated, at least in part, by bioactive
factors released from the ECs.
Phosphoinositide-3 kinase (PI3K)/Akt and mitogen activated
protein kinase (MAPK)/extracellular signal regulated kinase 1/2
(ERK 1/2) pathways regulate several cellular processes, including
cell survival [14,15]. Therefore, we analyzed the activation of Akt
and ERK pathways on CD34+ cells or CD34+-derived ECs
cultured in serum free-medium for 19 h and then treated with EC
or CD34+ cell-conditioned medium, respectively. The ratios
between phosphorylated and total proteins were determined by
a Multiplex assay (Fig. 4D). Interestingly, the ERK but not the
Akt pathway is activated in CD34+ cells by EC-conditioned
medium. Therefore, the pro-survival effect of EC-conditioned
medium in CD34+ cells seems to be mediated by the activation of
the ERK pathway. On the other hand, no significant activation
has been observed for ERK and Akt pathways in ECs by CD34+-
conditioned medium, as compared to the control.
To understand the crosstalk between both cells, we analysed the
cytokines secreted by CD34+ cells, CD34+-derived ECs, or both
cells encapsulated in fibrin gels, using a cytokine bead array
(Fig. 5). CD34+-derived ECs encapsulated in fibrin gels secrete
high levels (.100 pg/mL) of IL-6, IL-8, IL-13 and monocyte
chemotactic activating factor (MCAF) (Fig. 5A). On the other
hand, CD34+ cells encapsulated in fibrin gels secrete high levels
(.100 pg/mL) of IL-8, IL-13 and MCAF (Fig. 5B). Importantly,
when both cells are encapsulated together in fibrin gels, they
secrete high levels of the previous cytokines (IL-6, IL-8, IL-13 and
MCAF) and two additional cytokines, IL-10 and IL-17 (Fig. 5C).
These results confirm the existence of a crosstalk between CD34+-
derived ECs and CD34+ cells.
CD34+ cell adhesion to fibrin gels is enhanced in the
presence of CD34+-derived ECs or EC-conditioned
medium
To investigate the effect of the co-culture system in supporting
CD34+ cell adhesion, isolated CD34+ cells (100,000 cells/well)
were cultured on top of fibrin gels (i) in the presence of CD34+-
derived ECs (35,000 cells/well), (ii) in the absence of ECs, or (iii) in
the absence of ECs but in the presence of EC-conditioned
medium. To ascertain that any difference in adhesion that might
be noticed in the co-culture condition would be due to the
presence of ECs and not to cell number, 135,000 CD34+ cells were
also cultured alone. After 7 days in culture, the non-adherent cells
were removed by washing and the adherent cells were counted by
phase-contrast microscopy. 5.5610.4% (n=17), 5.863.3%
(n=23), 22.4620.9% (n=15) and 44.2633.2% (n=18) of
CD34+ cells were attached to the gel when cultured in the
absence of ECs (initial 100,000 and 135,000 CD34+ cells), in the
presence of ECs, or in the absence of ECs but in the presence of
EC-conditioned medium, respectively (Fig. S5). CD34+ cell
adhesion was low when cells were cultured alone, regardless of
initial cell number. The differences in CD34+ cell recovery cannot
be explained by differences in cell apoptosis/necrosis, since only a
small fraction (below 10%) of the cells are affected by those
(Fig. 6A). However, cell apoptosis and necrosis are significantly
discouraged (P,0.05) when the cells are cultured in EC-
conditioned medium rather than basal medium.
CD34+ cell differentiation into ECs is enhanced in the
presence of CD34+-derived ECs
Next, we assessed the potential of the co-culture system to
support CD34+ cell differentiation into ECs. For that purpose,
Figure 3. Adhesion of CD34+ cells to different substrates. CD34+
cells were seeded on 24-well plates coated with fibrin gel, type I
collagen gel (2.5 mg/mL) and fibronectin (50 mg/mL), and incubated for
3 h at 37uC. Polystyrene culture wells were used as control. After that
time, the cells were washed and the attached ones were counted in six
random microscope fields (6200 magnification) for each replicate.
Results are average 6 SD, n= 6. * and ** denote statistical significance
(P,0.05 and P,0.01, respectively).
doi:10.1371/journal.pone.0016114.g003
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CD34+ cells (100,000 cells/well) were cultured on top of fibrin gels
(i) in the presence of CD34+-derived ECs (35,000 cells/well), (ii) in
the absence of ECs, or (iii) in the absence of ECs but in the
presence of EC-conditioned medium. After 7 days in culture, the
ability of the cells to take up Ac-LDL, an endothelial marker, was
evaluated by fluorescence microscopy (Fig. 6B). Uptake of DiI-
labeled Ac-LDL increased from 12% on isolated CD34+ cells to
70% after differentiation in the presence of CD34+-derived ECs
(P,0.001). A non-statistically significant increase was observed for
Ac-LDL uptake on CD34+ cells cultured on fibrin without cells
(basal medium, 7 days), compared to original CD34+ cells (time
zero). Therefore, the results indicate that CD34+ cell differenti-
ation into ECs is significantly improved in the presence of CD34+-
derived ECs. Because no statistical increase in Ac-LDL uptake was
observed for CD34+ cells cultured in EC-conditioned medium, the
endothelial differentiation of CD34+ cells is mediated by additional
factors to the ones secreted by the CD34+-derived ECs.
We also evaluated by qRT-PCR the differentiation of CD34+
cells in co-culture with ECs and encapsulated in fibrin gels for 10
days (Fig. 6C). The expression of EC markers (vWF and CD34)
was similar or higher than for ECs or CD34+ cells encapsulated in
fibrin gels, indicating that most of the cells in the gels express
endothelial markers.
Co-transplantation of CD34+ cells with CD34+-derived
ECs improves wound healing in diabetic mice
The therapeutic effect of our tissue engineering approach was
further evaluated in a chronic wound animal model. Wounds were
created at the anterior and posterior dorsal regions of streptozot-
ocin-induced diabetic mice. One of the wounds was covered with
fibrin gel alone or PBS to serve as internal control, whereas the
other wound was covered with gel containing 16105 CD34+ cells,
or 0.356105 CD34+-derived ECs, or 16105 CD34+ cells with
0.356105 CD34+-derived ECs. At day 3 post-wounding, the
wound area was statistically lower in wounds treated with the gel
containing a co-culture of CD34+ cells with ECs compared to
wounds treated with PBS (P,0.05, n=6), indicating improved
closure kinetics (Fig. 7A). No statistical difference was observed for
the remaining experimental groups against the control (P.0.05,
n=6). To ascertain that the significant area reduction observed in
wounds treated with a co-culture of both cell types in fibrin gel was
due to the presence of the two different cell types, rather than to
cell number, some wounds were treated with 1.356105 CD34+
cells encapsulated in fibrin gels. No statistically significant wound
area reduction against the control was observed for this
experimental condition (Fig. S6). At day 10, although not
statistically different, wounds treated with the gel containing the
Figure 4. Viability of encapsulated cells. A) Viability of encapsulated cells, as assessed by a LIVE/DEAD assay. Results are average 6 SD, n= 3. B)
Mitochondrial metabolic activity of encapsulated cells. Results are average 6 SD, n= 6. Each absorbance at 540 nm was normalized by day 2
absorbance. C) Viability of encapsulated cells, as quantified by a LIVE/DEAD assay. Results are average 6 SD, n= 3. In all figures, * denote statistical
significance within time group: * P,0.05, **P,0.01, *** P,0.001. # denotes statistical significance between time groups comparing the respective
control/treatment groups: # P,0.05, ## P,0.01. D) Phosphorylated Akt/total Akt and phosphorylated ERK/total ERK ratios assessed by a Bio-Plex
phosphoprotein detection assay. Results are average 6 SD, n= 3.
doi:10.1371/journal.pone.0016114.g004
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co-culture of cells showed a greater area reduction compared to
wounds treated with PBS. Such differences between the
experimental group and control group were not observed for the
remaining groups. At this stage, the wound healing in all
experimental groups was characterized by reepithelialization,
dermal cellular infiltration and formation of granulation tissue
(Fig. S7).
We next evaluated the survival of the transplanted cells using a
non-invasive real time fluorescence imaging (CellVizio). At day 3,
cell survival was low (8.9611.7%, n=4) in wounds treated with a
co-culture of CD34+ and CD34+-derived ECs. At day 10, qRT-
PCR analyses of excised wounds showed the absence of human
cells (data not shown). This suggests that the therapeutic effect of
the cell co-culture is likely produced at the early phases of the
Figure 5. Multiplex cytokine analysis. Analysis of cytokines secreted by (A) CD34+-derived ECs grown on tissue culture polystyrene or
encapsulated in fibrin gels for 2 or 10 days, (B) CD34+ cells grown on tissue culture polystyrene or encapsulated in fibrin gels for 2 or 10 days and (C)
co-culture of CD34+ and CD34+-derived ECs encapsulated in fibrin gels for 2 or 10 days. Cell media were collected after being in contact with the cells
for 2 days. Results are average 6 SD, n= 3.
doi:10.1371/journal.pone.0016114.g005
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healing process and therefore the therapeutic benefit of stem cells
was not examined for a longer period of time.
Co-transplantation of CD34+ cells with CD34+-derived
ECs increases early neovascularization and decreases
inflammatory processes
Because stem cells and progenies can contribute for the
regeneration of the tissues through neovascularization, we assessed
the capillary density by immunofluorescence using vWF as a
vascular marker, at days 3 and 10 (Figs. 7B and 7C). At day 3, a
significant increase in the density of microvessels was observed for
the experimental groups containing stem cells relatively to the
group of the gel alone (P,0.001). This indicates that part of the
regenerative effect might be mediated through a neovasculariza-
tion process. Although the microvessel density increased in all
experimental groups at day 10, the difference between those of
cell-treated wounds and controls attenuated with time (from 3 to
10 days), in line with observations from other studies of wound
regeneration with stem cells [7].
The regenerative effect of stem cells and their progenies might
be also mediated by a reduction of inflammation at the wound site.
Therefore, the expression of inflammatory markers was assessed
by qRT-PCR at day 3 post-wounding. Myeloperoxidase (MPO),
CD3e and tumor necrosis factor-alpha (TNF-a) are markers for
the presence of neutrophils, T cells and inflammatory cytokines,
respectively. Although not statistically significant (P.0.05, n=9),
the inflammatory reaction (considering all three markers) in the
wounds treated with gel containing a co-culture of CD34+ cells
and CD34+-derived ECs (Fig. S8) was reduced compared to the
control, i.e. wounds treated with the gel alone. This effect was
further confirmed at protein level, by a multiplex assay (Fig. 7D).
In line with previous studies [16], IL-1b, TNF-a, IL-6 and GM-
CSF are expressed in all experimental groups at early stages
during the healing process. However, the secretion of TNF-a was
statistically (P,0.05) higher in wounds with gel alone than in
wounds treated with gel encapsulating CD34+ and CD34+-derived
ECs or CD34+ cells alone (Fig. 7D). These results indicate that
stem cells and their progenies are able to attenuate the
inflammatory process at the site of injury, contributing to the
healing progression.
Discussion
This work reports a methodology to improve the survival,
vascular differentiation and regenerative potential of UCB-derived
stem cells. The methodology is based on three components that
can be isolated or derived from UCB: hematopoietic stem cells
Figure 6. Viability and differentiation of CD34+ cells cultured on top of fibrin gels and gene expression analysis of encapsulated
cells. A) Apoptosis and necrosis of CD34+ cells cultured for 7 days on top of fibrin gels, in EGM-2 medium or EGM-2 medium conditioned by CD34+-
derived ECs. Results are average 6 SD, n=3 (magnification of6100). B) CD34+ cell differentiation on top of fibrin gels for 7 days in the absence (B.1)
or in the presence (B.2) of CD34+-derived ECs. B.3 shows the percentage of cells able to uptake Ac-LDL. Results are average 6 SD, n= 18. C)
Quantitative RT-PCR analysis of CD34+, CD34+-derived ECs, or a co-culture of both cells, encapsulated in fibrin gels for 10 days. Results are average 6
SD, n= 4. In all figures, * denote statistical significance: * P,0.05, **P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0016114.g006
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(CD34+ cells), CD34+-derived ECs to improve stem cell survival
and coach their differentiation into vascular cells, and fibrin gel to
retain both cells at the implant site. We show that diabetic chronic
wounds treated with a combination of both types of cells
encapsulated in a fibrin gel have improved healing compared to
wounds treated with gel containing only stem cells.
Figure 7. Regenerative effect of encapsulated CD34+ cells and CD34+-derived ECs on diabetic wounds. A) Wound closure (relatively to
initial wound area) in diabetic mice treated by topical application of 16105 CD34+ cells and 0.356105 CD34+-derived ECs (A.1), CD34+ cells (A.2) or
CD34+-derived ECs (A.3), encapsulated in fibrin gels. Control wounds received a saline solution (PBS) only. Results are average6 SEM, n=6. * denotes
statistical significance (P,0.05). B) Representative images of vWF immunostaining of wounds at day 3. Scale bar represents 50 mm. C) Quantification
of wound capillary density (number of capillaries per mm2), based on the vWF immunostaining results, for 3 and 10 day-old wounds in the different
experimental groups. Results are average 6 SEM, n=3. ** denotes statistical significance (P,0.001). D) Cytokine expression on mouse wound
samples excised 3 days post-wounding, as determined by a Bio-Plex mouse cytokine assay. Wounds had been treated by topical application of CD34+
cells or CD34+ cells plus CD34+-derived ECs encapsulated in fibrin gels. Control wounds received fibrin gel alone. Results are average 6 SD, n=3.
doi:10.1371/journal.pone.0016114.g007
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Our results indicate that fibrin gels support higher CD34+ cell
adhesion than collagen gels, fibronectin or tissue culture
polystyrene. Fibrin gels obtained by the crosslinking of fibrinogen
by thrombin, two plasma-derived components [17], have RGD
and AGDV sites through which they can interact with cell
integrins. Our findings agree with previous studies showing that
fibrin-containing thrombi provide local cues for initial adhesion of
peripheral blood-derived CD34+ cells [18].
ECs differentiated from UCB-derived CD34+ cells have superior
angiogenic properties than primary ECs (HUVECs). This is
confirmed by their ability to secrete higher levels of angiogenic
factors, including VEGF, PlGF and bFGF, and to produce a higher
number of sprouts and larger network in Matrigel (Fig. 2). This
seems to be specific for ECs derived from cord blood, since
peripheral blood-derived human endothelial progenitor cells have
angiogenic properties similar to HUVECs [19].
When both CD34+ cells and CD34+-derived ECs are
encapsulated in fibrin gels, they crosstalk, as confirmed by the
secretion of specific cytokines. CD34+-derived ECs encapsulated
alone in fibrin gels secreted high levels of IL-6, IL-8, IL-13 and
MCAF, while CD34+ cells encapsulated alone in fibrin gels
produced high levels of IL-8, IL-13 and MCAF. The secretion
profile of CD34+ cells is consistent with previous studies [20,21].
When both types of cells were concurrently encapsulated in fibrin
gels, they secreted two novel cytokines, cytokine IL-17 and IL-10,
in addition to the ones secreted by each type of cell. IL-17 is a
cytokine that has been reported to be produced by T lymphocytes
and monocytes [22] and thus it is likely secreted by CD34+ cells,
acting subsequently in ECs [23]. This is because human vascular
ECs, but not CD34+ cells, express the IL-17 receptor (IL-17 R)
[24]. The binding of IL-17 in ECs stimulates the production of IL-
6, IL-8, transforming growth factor b (TGF-b) and MCAF and
stimulates EC migration and tube formation [25]. IL-10 is a
cytokine produced by various cell populations, including CD34+
cells and ECs [26]. IL-10 activity is mediated by its interaction
with the IL-10 receptor, expressed on a variety of cells, including
CD34+ cells and ECs [27]. In our study, it is unclear whether IL-
10 was secreted by CD34+ cells or CD34+-derived ECs and
whether IL-10 is acting on either both cells or only one type of
cells. Importantly, it has been reported that IL-10 increases Bcl-2
expression and survival in CD34+ cells [28].
In this study, we show that the adhesion, viability, proliferation
and vascular differentiation of CD34+ cells in fibrin gels are
improved by co-culturing these cells with CD34+-derived ECs.
Importantly, the pro-survival effect is specific for CD34+-derived
ECs, since primary ECs (HUVECs) have no such effect. Our
results also indicate that CD34+ cell survival, proliferation and
adhesion to fibrin gels are mediated by biomolecules secreted by
CD34+-derived ECs, since conditioned medium collected from
these cells has similar inductive effects. However, CD34+ cell
differentiation into ECs requires additional factors to the ones
secreted by ECs, since CD34+-derived EC-conditioned medium
alone does not improve CD34+ cell differentiation.
The improved adhesion and viability of CD34+ cells in the
presence of CD34+-derived ECs is likely mediated by growth
factors and cytokines. VEGF [29], IL-3 [30], IGF-I [31] and IL-10
[28] have been reported to be involved in the survival of CD34+
cells. We show that VEGF is highly expressed at gene level both in
CD34+ cells and in CD34+-derived ECs encapsulated in fibrin gels
(Fig. 7), and thus might account for the improved survival of
CD34+ cells. Another factor that might contribute to the survival
of CD34+ cells is IL-10 (see above). Our study also indicates that
the improved adhesion of CD34+ cells in the presence of ECs is
mediated by soluble factors. It has been shown that binding of
soluble P-selectin, expressed by ECs, to P-selectin glycoprotein
ligand-1 (PSGL-1), expressed by CD34+ cells, activates cellular
adhesion molecules on CD34+ cells, particularly avb5 integrins
[18]. The expression of these integrins favors the adhesion to
fibrinogen [18]. A similar mechanism might explain the improved
cellular adhesion in our co-culture system.
Our in vitro results show that the ERK, but not the Akt pathway, is
activated in starved CD34+ cells treated with EC-conditioned
medium. Therefore, a likely mechanism for CD34+ cell protection
mediated by ECs is via activation of ERK. This finding is in line with
recent data showing that transient activation of the ERK signaling
pathway results in the survival and expansion of CD34+ cells [32].
CD34+-derived ECs, but not medium conditioned by these cells,
rapidly induce the differentiation of CD34+ cells into ECs. CD34+
cells cultured for 7 days in the presence of CD34+-derived ECs are
able to uptake DiI-labeled Ac-LDL (70% of the cells), a functional
feature of ECs. These results suggest an early involvement of cell-
cell interactions or extracellular matrix synthesized by ECs in the
induction of vascular differentiation. Yet, the induction mechanism
is still unknown. Interestingly, induction of vascular differentiation
by extracellular matrix produced by ECs has been described
recently for mesenchymal stem cells [33].
Diabetic ulcers are difficult to heal and innovative treatments to
enhance wound healing and regeneration are needed [4]. One of
the treatments being pursued involves the application of stem cells,
relying on the assumption that topical application of stem cells
modulates the healing response. Few studies have demonstrated
the therapeutic benefit of stem cells in diabetic ulcers [7,8]. Bone
marrow-derived mesenchymal stem cells have been reported to
enhance wound healing in diabetic mice, associated with increased
angiogenesis [8]. This effect is mediated by factors secreted by
these cells, including epidermal growth factor, keratinocyte growth
factor, VEGF, bFGF, IL-6 and MCP-1 [34]. A similar paracrine
effect has been documented recently for fetal progenitor cells
(CD133+ cells) administered topically to diabetic wounds [7]. It
was shown that stem cell released factors (e.g. VEGF and IL-8)
stimulate angiogenesis and activate Wnt signaling, promoting the
healing of diabetic ischemic ulcers.
The therapeutic effect of CD34+ cells or the combination of
CD34+ cells with CD34+-derived ECs was tested in streptozotocin-
induced diabetic mice which have previously been used to study
the effect of allogeneic cell-based therapies on diabetic wound
healing without immunosuppressant [7]. Although C57BL/6 mice
are not immunocompromised, studies have demonstrated that
human umbilical cord cells may be administered to other species
for therapeutic benefit, in the absence of immune suppression,
with low cross-species reactivity [35,36]. In one case, cells have
survived for 1 month after allogeneic transplantation [10] likely
due to their immunological immaturity.
Importantly, no study to date has documented the regenerative
potential of UCB-derived CD34+ cells in the context of diabetic
wounds. Here, we show that the transplantation of CD34+ cells
together with CD34+-derived ECs, but not CD34+ cells or CD34+-
derived ECs alone, in fibrin gels enhances wound healing,
compared to wounds covered with gel alone or PBS. A substantial
fraction of cells (more than 90%) died over a 3-day period. This is
in line with other studies showing a dramatic decline of stem cells
at the injury site [7,37]. Even so, a therapeutic benefit was
observed over the 10 day period in our study, likely due to factors
secreted by both cells, which increased neovascularization and
decreased the inflammatory reaction. As noted before, cytokines
IL-10 and IL-17 are only secreted when both cells are co-cultured.
IL-10 is a potent immunosuppressant of monocyte/macrophage
functions, inhibiting the production of pro-inflammatory cytokines
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[38]. We attempted to quantify human IL-10, IL-17 and other
cytokines (IL-6, IL-8, MCF, among others) in the biopsies of
wounds treated with the co-culture system for 3 days; however, the
levels of all human cytokines were below the sensitivity of the
Multiplex assay. The dilution effect of the human cytokines by the
mouse proteins as well as the low survival of the cells at day 3 may
explain the low levels of cytokines. Finally, our Multiplex results
also indicate that the level of TNF-a, a pro-inflammatory cytokine,
was lower for wounds treated with CD34+ cells and ECs, or only
CD34+ cells encapsulated in fibrin gel.
Collectively, our data show that the therapeutic potential of
hematopoietic stem cells derived from cord blood is enhanced
when they are co-cultured with their vascular progenies. The
crosstalk between hematopoietic stem cells and vascular cells is
beneficial for their adhesion, survival, differentiation and thera-
peutic effect. To improve the therapeutic benefit of the cell co-
culture, multiple applications, rather than a single application of
the cells encapsulated in fibrin gel, could be performed. Further
studies are needed to address the potential of this approach. We
postulate that this co-culture system may have potential thera-
peutic applications, not only in chronic wounds, but also in other
vascular and ischemic problems.
Supporting Information
Figure S1 Characterization of HUVECs by immunoflu-
orescence. Cells express high levels of CD31, vWF and VE-
CAD, low levels of CD34, have the ability to uptake Ac-LDL and
do not express typical smooth muscle cell markers such as a-SMA
and SM-MHC. Bar corresponds to 20 mm.
(TIFF)
Figure S2 Ability of vascular cells to form networks in
Matrigel. CD34+-derived ECs as well as HUVECs form cords
when seeded in Matrigel for 48 h. Bar corresponds to 40 mm.
(TIFF)
Figure S3 Effect of cell number on the gel contraction
and in the viability of CD34+ cells encapsulated in fibrin
gels. A) Variation of gel diameter over time for constructs having
a defined number of CD34+ cells. For all experimental groups, low
gel contraction is observed after 10 days. B) Viability of
encapsulated CD34+ cells, as assessed by a LIVE/DEAD assay.
The assay was performed at days 2, 6 and 10. Cell viability is
affected by the number of cells encapsulated in the gel. Results are
average 6 SD, n=3 (3 readings per construct).
(TIFF)
Figure S4 Degradation of fibrin gels containing cells. A)
Degradation of fluorescently-labeled fibrin gels containing 16105
CD34+ cells, or 0.356105 CD34+-derived ECs, or a co-culture of
both cells at these numbers. Low degradation of fibrin gels is
observed for all experimental groups. B) Variation of gel diameter
over time. Low gel contraction is observed after 10 days. Results
are average 6 SD, n=3. * denotes statistical significance within
time group: ** P,0.01. # denotes statistical significance between
time groups comparing the respective control/treatment groups:
# P,0.05, ## P,0.01.
(TIFF)
Figure S5 Adhesion of CD34+ cells to fibrin gels. CD34+
cells were seeded on 24-well plates coated with fibrin gels either
with (C) or without (A, B and D) CD34+-derived ECs (35,000
cells). The number of CD34+ cells per well was 100,000, except in
B (135,000). The culture medium was EGM-2, except in D (EC-
conditioned EGM-2). After 7 days, the cells were washed and the
attached ones were counted in random microscope fields (6200
magnification). Results are average 6 SD. * and *** denote
statistical significance (P,0.05 and P,0.0001, respectively).
(TIFF)
Figure S6 Regenerative effect of CD34+ cells encapsu-
lated in fibrin gels on diabetic wounds. Wound closure
(relatively to initial wound area) in diabetic mice treated by topical
application of 1.356105 CD34+ cells encapsulated in fibrin gels.
Control wounds received a saline solution (PBS) only. Results are
average 6 SEM, n=5.
(TIFF)
Figure S7 Histological analysis of wounds treated by
topical application of fibrin gel alone or fibrin gel
containing CD34+ cells or CD34+ cells plus CD34+-
derived ECs. Representative bright-field photographs of mouse
wounds at day 10, stained with hematoxylin/eosin. Bar corre-
sponds to 100 mm.
(TIFF)
Figure S8 Expression of inflammation-related genes by
quantitative RT-PCR, on mouse wound skin biopsies at
day 3. Wounds had been treated by topical application of fibrin
gel containing 16105 CD34+ cells and 0.356105 CD34+-derived
ECs. Control wounds were covered with gel only. Results are
average 6 SD, n=9.
(TIFF)
Table S1 Primer sequences used for qPCR.
(TIFF)
Materials and Methods S1 Expanded materials and methods
section.
(DOC)
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